ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Optimization of Human Liver Organoid Model for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

Y. Park1, D. Thadasina1, K. Isidan1, K. J. Lopez1, A. Cross-Najafi1, P. Li1, H. Francis2, G. Alpini2, W. Zhang1, B. Ekser1

1Surgery, Indiana University School of Medicine, Indianapolis, IN, 2Division of Gastroenterology & Hepatology, Indiana University School of Medicine, Indianapolis, IN

Meeting: 2022 American Transplant Congress

Abstract number: 181

Keywords: Bioengineering, Hepatocytes, Liver, Liver metabolism

Topic: Basic Science » Basic Science » 06 - Tissue Engineering and Regenerative Medicine

Session Information

Session Name: Cellular/Islet Therapies and Tissue Engineering

Session Type: Rapid Fire Oral Abstract

Date: Sunday, June 5, 2022

Session Time: 5:30pm-7:00pm

 Presentation Time: 6:20pm-6:30pm

Location: Hynes Room 310

*Purpose: The aim of our project is to develop an in vitro 3D human liver organoid (3D-HLO) model for studying nonalcoholic fatty liver disease (NAFLD) and its advanced form, nonalcoholic steatohepatitis (NASH), by mimicking the in vivo niche pathophysiological liver microenvironment.

*Methods: 3D-HLOs were created by incorporating primary human hepatic cells isolated from healthy donor livers, including hepatocytes (HCs), hepatic stellate cells, liver sinusoidal endothelial cells, cholangiocytes, and Kupffer cells (Fig. 1A, B). EIA and biochemistry assays were performed to evaluate urea synthesis and secretion of albumin and total bile acids. NAFLD was modeled by subjecting 3D-HLOs to a 7-day treatment of free fatty acid (FFA) and lipopolysaccharide (LPS) to induce steatosis, fibrosis, and inflammation. Lipid accumulation and fibrosis were detected with Nile Red and Sirius Red staining, respectively. 3D-HLOs generated using HCs isolated from a NAFLD patient (Fig. 1C), and treated with obeticholic acid (OCA, 1μM) and lanifibranor (10μM) for 7 days. RT-qPCR and LDH cytotoxicity assay were performed to determine the hepatocyte phenotype, cytotoxicity, and fibrosis in normal and NAFLD 3D-HLOs.

*Results: RT-qPCR and immunofluorescence staining for expression of ALB, CYP3A4, and CYP1A2 demonstrated that 3D-HLOs maintained a mature liver phenotype for up to 30 days. Furthermore, liver functions including urea synthesis, albumin production, and total bile acid secretion were also maintained for up to 30 days (Fig. 1D). Nile Red and Sirius Red staining showed that 3D-HLOs treated with FFA+LPS had increased lipid accumulation and collagen deposition, respectively, compared to FFA alone or control (Fig. 1E). In the NAFLD 3D-HLOs, we found that OCA and lanifibranor upregulated the expression of CYP3A4 and ALB, respectively, and both repressed the expression of Col1A1. LDH cytotoxicity assay further demonstrated that lanifibranor repressed cell death in FFA-treated NAFLD 3D-HLOs.

*Conclusions: Despite the rising incidence of NAFLD/NASH, there is no FDA-approved therapy for treatment, and the disease mechanism is still elusive. Our 3D-HLOs provide an ex vivo human liver model to study the pathogenesis of NAFLD/NASH and screen novel therapeutic strategies.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Park Y, Thadasina D, Isidan K, Lopez KJ, Cross-Najafi A, Li P, Francis H, Alpini G, Zhang W, Ekser B. Optimization of Human Liver Organoid Model for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/optimization-of-human-liver-organoid-model-for-nonalcoholic-fatty-liver-disease-and-nonalcoholic-steatohepatitis/. Accessed May 9, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences